DNTH Dianthus Therapeutics, Inc. /DE/
8-K Current Report
Filed: March 9, 2026
Health Care
Pharmaceutical PreparationsDianthus Therapeutics, Inc. /DE/ (DNTH) 8-K current report filed with SEC EDGAR on March 9, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.
Reported 8-K Items3 items
- Item 7.01: Regulation FD Disclosure
- Item 8.01: Other Events
- Item 2.02: Results of Operations and Financial Condition
AI Filing Analysis8-K
Item 2.02 · Results of Operations and Financial Condition
- • Q4 and full-year 2025 earnings released March 9, 2026 — full financials in Exhibit 99.1
- • Filing "furnished" not "filed" — standard for earnings releases, limits legal liability under Exchange Act
Item 7.01 · Regulation FD Disclosure
- • Phase 3 CAPTIVATE trial of claseprubart in CIDP received early "GO" decision following interim responder analysis
- • GO decision signals pre-specified efficacy threshold met mid-trial — typically a strong positive catalyst for clinical-stage biotech
Item 8.01 · Other Events
- • Dianthus filed multiple exhibits on March 9, 2026, including a dedicated data press release and data presentation — signals clinical or preclinical trial results disclosed
- • Dual data releases (99.2 + 99.3) suggest structured presentation of study findings, likely for an investor/medical conference or regulatory milestone
Other Dianthus Therapeutics, Inc. /DE/ 8-K Filings
Get deeper insights on Dianthus Therapeutics, Inc. /DE/
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.